79 related articles for article (PubMed ID: 30086162)
1. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
Nucera C; Lawler J; Hodin R; Parangi S
Oncotarget; 2010 Dec; 1(8):751-756. PubMed ID: 21321384
[TBL] [Abstract][Full Text] [Related]
2. Iodine nutritional status is not a direct factor in the prevalence of the
Lin YY; Hsieh YS
Arch Endocrinol Metab; 2023 Mar; 67(2):172-178. PubMed ID: 36651704
[TBL] [Abstract][Full Text] [Related]
3. Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects.
Landa I; Thornton CEM; Xu B; Haase J; Krishnamoorthy GP; Hao J; Knauf JA; Herbert ZT; Martínez P; Blasco MA; Ghossein R; Fagin JA
Mol Cancer Res; 2023 Nov; 21(11):1163-1175. PubMed ID: 37478162
[TBL] [Abstract][Full Text] [Related]
4. Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family.
Kumar A; Bandapalli OR; Paramasivam N; Giangiobbe S; Diquigiovanni C; Bonora E; Eils R; Schlesner M; Hemminki K; Försti A
Sci Rep; 2018 Aug; 8(1):11635. PubMed ID: 30072699
[TBL] [Abstract][Full Text] [Related]
5. Evolution of resistance to thyroid cancer therapy.
Nucera C
Aging (Albany NY); 2016 Aug; 8(8):1576-7. PubMed ID: 27575377
[No Abstract] [Full Text] [Related]
6. Genomic alterations in thyroid cancer: biological and clinical insights.
Landa I; Cabanillas ME
Nat Rev Endocrinol; 2024 Feb; 20(2):93-110. PubMed ID: 38049644
[TBL] [Abstract][Full Text] [Related]
7. Borealin/CDCA8 deficiency alters thyroid development and results in papillary tumor-like structures.
Didier-Mathon H; Stoupa A; Kariyawasam D; Yde S; Cochant-Priollet B; Groussin L; Sébag F; Cagnard N; Nitschke P; Luton D; Polak M; Carré A
Front Endocrinol (Lausanne); 2023; 14():1286747. PubMed ID: 37964961
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Insights of Thyroid Cancer Progression.
Leandro-García LJ; Landa I
Endocrinology; 2023 Aug; 164(9):. PubMed ID: 37503738
[TBL] [Abstract][Full Text] [Related]
9. MIEAP and ATG5 are tumor suppressors in a mouse model of BRAF
Hamada K; Kurashige T; Shimamura M; Arakawa H; Nakamura Y; Nagayama Y
Front Endocrinol (Lausanne); 2022; 13():932754. PubMed ID: 36187114
[TBL] [Abstract][Full Text] [Related]
10. Sex Bias in Differentiated Thyroid Cancer.
Suteau V; Munier M; Briet C; Rodien P
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884794
[TBL] [Abstract][Full Text] [Related]
11.
Innella G; Bonora E; Neri I; Virdi A; Guglielmo A; Pradella LM; Ceccarelli C; Amato LB; Lanzoni A; Miccoli S; Gasparre G; Zuntini R; Turchetti D
Front Med (Lausanne); 2021; 8():688105. PubMed ID: 34386506
[TBL] [Abstract][Full Text] [Related]
12. Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development.
Schoultz E; Johansson E; Moccia C; Jakubikova I; Ravi N; Liang S; Carlsson T; Montelius M; Patyra K; Kero J; Paulsson K; Fagman H; Bergo MO; Nilsson M
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34379110
[TBL] [Abstract][Full Text] [Related]
13. The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
Singh A; Ham J; Po JW; Niles N; Roberts T; Lee CS
Cells; 2021 May; 10(5):. PubMed ID: 34062862
[TBL] [Abstract][Full Text] [Related]
14. Acceleration of BRAF
Shimamura M; Kurashige T; Kuatov R; Nakashima M; Nagayama Y
Endocrine; 2020 Sep; 69(3):571-577. PubMed ID: 32281047
[TBL] [Abstract][Full Text] [Related]
15. Mouse Models as a Tool for Understanding Progression in Braf
Landa I; Knauf JA
Endocrinol Metab (Seoul); 2019 Mar; 34(1):11-22. PubMed ID: 30784243
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels.
Shimamura M; Shibusawa N; Kurashige T; Mussazhanova Z; Matsuzaki H; Nakashima M; Yamada M; Nagayama Y
PLoS One; 2018; 13(8):e0201365. PubMed ID: 30086162
[TBL] [Abstract][Full Text] [Related]
17. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
[TBL] [Abstract][Full Text] [Related]
18. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.
Knauf JA; Ma X; Smith EP; Zhang L; Mitsutake N; Liao XH; Refetoff S; Nikiforov YE; Fagin JA
Cancer Res; 2005 May; 65(10):4238-45. PubMed ID: 15899815
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.
Jolly LA; Novitskiy S; Owens P; Massoll N; Cheng N; Fang W; Moses HL; Franco AT
Cancer Res; 2016 Apr; 76(7):1804-13. PubMed ID: 26818109
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
